⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockHong KongNasdaqCM

RGC

Regencell Bioscience Holdings Limited

Healthcare · Drug Manufacturers - Specialty & Generic

7.67USD

-2.1400 (-21.81%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on RGC.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
Fiscal Year End06/2026
Last Quarter End12/2025 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 7.67
P/E—
Dvd Ind Yld0.0%
P/B3,119.15
P/S—
Curr EV/T12M EBITDA-325.5
Mkt Cap (USD)3.8B
Curr EV (USD)3.8B
2)

Per Share Data

EPS T12M-0.01
DPS—
Bk Val Per Sh0.03
Rev/Sh—
Cash/Sh0.03
Curr Shares Out495.9M
FCF/Sh-0.01
3)

Cash Flow Analysis

P/CF-950.5
Curr P/FCF-949.2
CF/NI0.9
Dvd P/O—
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales—
Eff Interest Rate—
4)

Growth Potential

Dil EPS 1Y Gr17.2%
Cap 1Y Gr-31.7%
BPS 1Y Gr-31.7%
R&D To Sales—
Retention Rate—
Rev 1Y Gr—
FCF 1Y Gr19.7%
Assets 1Y Gr-33.1%
5)

Profitability

EBITDA-0.0B
EBIT-0.0B
Operating Margin0.0%
Pretax Margin—
Net Margin0.0%
ROA-40.9%
ROE-47.1%
ROC—
Asset Turnover—
6)

Structure

Current Ratio12.18
Quick Ratio10.75
Debt/Assets9.8%
Debt/Com Eq24.3%
Net Debt/EBITDA0.67
Tot Debt/Capital19.5%
Gross Margin0.0%
EBIT/Int Exp—

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.